SAN
DIEGO, June 5, 2024 /PRNewswire/ -- Tempo
Therapeutics, Inc. ("Tempo"), a leading innovator in tissue
engineering and regenerative medicine, today announced the addition
of Eric I. Richman, MBA to its board
of directors.
"We are delighted to have Eric join the board at Tempo. His
extensive strategic and operational experience paired with his
proven track record of success in leading commercial and
development stage companies make him a strong addition to our Board
of Directors," stated Westbrook Weaver, Ph.D., Tempo's Chief
Executive Officer and Founder. "After the recent close of our
oversubscribed Series A round, Tempo advances its synthetic tissue
scaffold candidates based on the revolutionary Microporous Annealed
Particle (MAP) technology platform into clinical trials, and the
addition of Mr. Richman will maximize the chance for success and
value."
Eric has a long-standing and successful career in life sciences.
Eric began his career in biopharma venture capital at HealthCare
Ventures and served in key leadership roles in various biotech and
pharma services companies including MedImmune, Lev Pharma, ADMA
Biologics, Gain Therapeutics and LabConnect. He currently serves on
the boards of various biotech companies and is an advisor to
venture capital and private equity firms.
Marty Sands of Galaxy-Sirius
Partners (a lead investor in Tempo's Series A financing) said,
"Upon closing the Tempo Series A round, we had the responsibility
to appoint a board member. Our first selection was Eric Richman due to his vast, impressive, and
successful bio-science experiences. Tempo has a complex patented
technology with the potential to revolutionize internal surgical
outcomes. We view it as highly disruptive and revolutionary, and a
person with Eric's deep understanding of complex scientific
solutions can add tremendous value to a company that may have
the key to significantly improving surgical outcomes in multiple
areas. It is our view that Eric has the biotechnology experiences
to aid in developing and commercializing Tempo's transformative
technology as the upcoming clinical data begins to come
in."
About MAP Technology:
The Microporous Annealed Particle (MAP) technology is a
first-in-class volumetric injectable porous scaffolding for
regenerative medicine. The MAP technology enables Tempo to
repurpose established hydrogel polymer components with strong
safety profiles by assembling them into a hyper-porous, flowable
scaffold format. MAP-based products immediately allow tissue
ingrowth and integration upon application. Tissue implants using
MAP technology are able to evade the typical inflammatory and
scar-forming Foreign Body Response (FBR) and instead promote a
regenerative immune response that leads to accelerated formation of
vascularized tissue volume.
About Tempo Therapeutics
Tempo Therapeutics is a privately held, clinical-stage
technology company pioneering the future of tissue engineering. The
Company is leveraging its patented Microporous Annealed Particle
(MAP) technology platform with a mission to harness the power of
immunomodulation and material science to transform the landscape of
medical technology by developing new synthetic biomaterials for use
in a variety of surgical reconstruction and therapeutic
regenerative applications.
For more information about Tempo Therapeutics and its innovative
MAP technology platform, please visit www.tempothera.com.
Forward- Looking Statements
Any statements in this release that are not historical facts may
be considered to be "forward-looking statements." Forward-looking
statements are based on management's current expectations and are
subject to risks and uncertainties which may cause results to
differ materially and adversely from the statements contained
herein. Such statements include, but are not limited to, statements
regarding the market opportunity for Tempo's product candidates,
and the business strategies and development plans of Tempo. Undue
reliance should not be placed on forward-looking statements, which
speak only as of the date they are made. Except as required by law,
Tempo does not undertake any obligation to update any
forward-looking statements to reflect new information, events or
circumstances after the date they are made, or to reflect the
occurrence of unanticipated events.
Contact:
Westbrook Weaver, Ph.D.
Chief Executive Officer, Tempo Therapeutics
Phone: (619) 202-7445
Email: info@tempothera.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/tempo-therapeutics-announces-appointment-of-eric-i-richman-to-board-of-directors-302165479.html
SOURCE Tempo Therapeutics, Inc